Compare · AGMB vs ARGX
AGMB vs ARGX
Side-by-side comparison of AgomAb Therapeutics NV (AGMB) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGMB and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.52B, about 128.0x AGMB ($410.2M).
- AGMB has been more active in the news (9 items in the past 4 weeks vs 6 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 7 for AGMB).
- Company
- AgomAb Therapeutics NV
- argenx SE
- Price
- -
- -
- Market cap
- $410.2M
- $52.52B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- 2017
- News (4w)
- 9
- 6
- Recent ratings
- 7
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest AGMB
- SEC Form 6-K filed by AgomAb Therapeutics NV
- Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
- SEC Form 4 filed by AgomAb Therapeutics NV
- Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
- SEC Form 4 filed by AgomAb Therapeutics NV
- SEC Form 4 filed by AgomAb Therapeutics NV
- SEC Form 4 filed by AgomAb Therapeutics NV
- SEC Form 6-K filed by AgomAb Therapeutics NV
- Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
- SEC Form 4 filed by Director Garcia Marino
Latest ARGX
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- SEC Form 6-K filed by argenx SE
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- SEC Form 6-K filed by argenx SE
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE